Chronic Kidney Disease Prognosis Consortium

摘要(标题：CKD-预测联盟) 慢性肾脏病(CKD)是一种全球公共卫生流行病，影响10%-16%的成年人 亚洲、欧洲和北美的人口。慢性肾脏病的临床影响是巨大的：风险 终末期肾病(ESRD)、心血管疾病(CVD)和过早死亡的比例为 都变高了。尽管取得了实质性进展，但仍有几个问题悬而未决 CKD流行病学领域，部分原因是分析策略、测量方法的异质性 已发表的研究中使用的肾脏疾病标记物和结果定义。一个严谨的， 需要使用广泛的全球收集的数据的统一方法来巩固 CKD管理、研究计划和预防策略的证据。 CKD预测联盟(CKD-PC)成立于2009年，使用的种子资金来自 国家肾脏基金会，目前由来自世界各地50个队列的约200名调查人员组成； 每年都有新的队伍加入。以估计的肾小球滤过率(EGFR)和蛋白尿 测量250万名代表一般、高心血管风险和慢性肾脏病的参与者 在这方面，CKD-PC制定了生产高影响文件的记录。CKD-PC 通过代表广泛的全球人口来补充已建立的CKD队列， 涵盖所有范围的肾功能，并在存在适当数据的情况下进行荟萃分析。 使用具有统一、集中分析的流动结构，CKD-PC将追求三大目标： 目的1：确定慢性肾脏病进展与终末期肾病风险、死亡率和其他疾病的关系。 结果。这将为临床试验的替代结果的选择和跟踪提供信息 与慢性肾脏病进展有关的患者。 目标2：开发CKD相关结局(如CVD和ESRD)的风险预测模型 覆盖了一系列的患者群体。这些风险评分将为临床决策提供信息。 目标3：与财团成员密切合作，寻求更多的高优先议题。 我们正在扩大结果、风险因素和方法研究的范围。 目标包括18个稿件主题；我们计划出版至少四个严格的元- 每年都会进行分析。我们将全方位加强CKD措施的标准化和 结果，制定严谨和创新的统计方法，并分享分析工具和 技术跨越队列和与公众。CKD-PC之前的工作已经 已被证明对临床指南和FDA在临床试验中对CKD进展的评估很有用。 这笔拨款将为解决重要问题的持续生产力提供资金。

ABSTRACT (TITLE: CKD-PROGNOSIS CONSORTIUM) Chronic kidney disease (CKD) is a global public health epidemic, affecting 10-16% of the adult population in Asia, Europe, and North America. The clinical impact of CKD is substantial: risks of end stage renal disease (ESRD), cardiovascular disease (CVD), and premature mortality are all heightened. Despite substantial progress, there are several unanswered questions in the field of CKD epidemiology, in part due to the heterogeneity of analytic strategies, measurement of kidney disease markers, and outcome definitions used in published studies. A rigorous, uniform approach using extensive, globally collected data is needed to solidify the foundation of evidence for CKD management, research initiatives, and strategies for prevention. The CKD Prognosis Consortium (CKD-PC) was formed in 2009 using seed money from the National Kidney Foundation and now comprises ~200 investigators from 50 cohorts world-wide; new cohorts join each year. With estimated glomerular filtration rate (eGFR) and albuminuria measures in >2.5 million participants representing general, high cardiovascular risk, and CKD populations, the CKD-PC developed a track record of producing high impact papers. CKD-PC complements established CKD cohorts by representing a broad range of global populations, spanning the full range of kidney function, and meta-analyzing where appropriate data exist. Using a fluid structure with uniform, centralized analytics, CKD-PC will pursue three broad aims: Aim 1: To determine the relationship of CKD progression to risk of ESRD, mortality, and other outcomes. This will inform selection of surrogate outcomes for clinical trials and tracking of patients with respect to CKD progression. Aim 2: To develop risk prediction models for CKD-related outcomes (e.g., CVD and ESRD) across a range of patient populations. These risk scores will inform clinical decision making. Aim 3: To pursue additional high priority topics in close collaboration with consortium members. We are expanding the range of outcomes, risk factors, and methodologic research. The aims comprise 18 manuscript topics; we plan to publish at least four rigorous meta- analyses each year. At all steps, we will work to improve standardization of CKD measures and outcomes, develop rigorous and innovative statistical methods, and share analytical tools and techniques across cohorts and with the public. Previous work by the CKD-PC has already proved useful for clinical guidelines and FDA evaluation of CKD progression in clinical trials. This grant would fund sustained productivity addressing important questions.